Marked increase in proton pump inhibitors use in Australia

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 10, 2010, Pages 1019-1024

  Hollingworth, Samantha ^a   Duncan, Emma L ^a,b   Martin, Jennifer H ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Gastro oesophageal reflux disease; Prescribing; Proton pump inhibitors; Utilisation

Indexed keywords

CIMETIDINE; ESOMEPRAZOLE; FAMOTIDINE; LANSOPRAZOLE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE;

AGED; ARTICLE; AUSTRALIA; DRUG COST; DRUG MARKETING; DRUG UTILIZATION; FEMALE; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT INDICATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUSTRALIA; CHILD; CHILD, PRESCHOOL; DRUG COSTS; DRUG UTILIZATION; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; HEARTBURN; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PHARMACOPOEIAS AS TOPIC; PHYSICIAN'S PRACTICE PATTERNS; PROTON PUMP INHIBITORS; YOUNG ADULT;

EID: 79251491014     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1969     Document Type: Article

References (44)

1. AIHW Australian GP Statistics And Classification Centre. Gastrointes-Tinal Symptoms And Management Among General Practice Patients. SAND Abstract No. 121 From The BEACH Program (Bettering The Evaluation And Care Of Health). Supplementary Analysis Of Nominated Data. Sydney: AGPSCC, University Of Sydney., 2008.
2. Westbrook JI, Talley NJ. Diagnostic investigation rates and use of prescription and non-prescription medications amongst dyspeptics: a population-based study of 2300 Australians. Aliment Pharmacol Ther 2003; 17(9): 1171-1178.
3. Helander HF. Physiology and pharmacology of the parietal cell. Baillieres Clin Gastroenterol 1988; 2(3): 539-554.
4. Drug Utilisation Sub-Committee (DUSC). Top 10 drugs. Australian Prescriber 2006; 29: 167.
5. Department of Health and Ageing. Schedule of Pharmaceutical Benefits for Approved Pharmacists and Medical Practitioners. Canberra: Australian Government Publishing Service 2007
6. Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther 2000; 25(5): 333-340.
7. Canadian Agency for Drugs and Technologies in Health. Canadian Optimal Medication Prescribing & Utilization Service (COMPUS) Program - Proton Pump Inhibitors 2007.
8. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. Br Med J 2008; 336(7634): 2-3.
9. World Health Organisation. WHO Collaborating Centre for Drug Statistics Methodology, 2008.
10. Australian Bureau of Statistics. Population by Age and Sex, Australian States and Territories. Cat. No. 3201.0: Australian Bureau of Statistics, 2007.
11. Berger JO. Statistical Decision Theory and Bayesian Analysis (2nd edn), Springer-Verlag: New York, 1985.
12. Sterne JA, Davey Smith G. Sifting the evidence-what's wrong with significance tests? Br Med J 2001; 322(7280): 226-231.
13. Australian Government Department of Health and Ageing. Australian Statistics on Medicines 2006. Department of Health and Ageing: Canberra, 2008.
14. Peach HG, Pearce DC, Farish SJ. Helicobacter pylori infection in an Australian regional city: prevalence and risk factors. Med J Aust 1997; 167(6): 310-313.
15. Szucs T, Thalmann C, Michetti P, Beglinger C. Cost analysis of longterm treatment of patients with symptomatic Gastroesophageal Reflux Disease (GERD) with esomeprazole on-demand treatment or esomeprazole continuous treatment: an open, randomized, multicenter study in Switzerland. Value Health 2008.
16. Food and Drug Administration. Esomperazole. Clinical Pharmacology and Biopharmaceutics Review. Appplication Number: 21-153/21-154. Centre for Drug Evaluation and Research, 2001.
17. Knox SA, Harrison CM, Britt HC, Henderson JV. Estimating prevalence of common chronic morbidities in Australia. Med J Aust 2008; 189(2): 66-70.
18. Cresswell KM, Fernando B, McKinstry B, Sheikh A. Adverse drug events in the elderly. Br Med Bull 2007; 83: 259-274.
19. Friedman AL, Geoghegan SR, Sowers NM, Kulkarni S, Formica RN Jr. Medication errors in the outpatient setting: classification and root cause analysis. Arch Surg 2007; 142(3): 278-283 discussion 84.
20. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301(9): 937-944.
21. PPI interactions with clopidogrel. Med Lett Drugs Ther 2009; 51(1303): 2-3.
22. Freedman JE, Hylek EM. Clopidogrel, genetics, and drug responsiveness. N Engl J Med 2009; 360(4): 411-413.
23. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28(13): 1598-1660.
24. McGowan B, Bennett K, Barry M, Canny M. The utilisation and expenditure of medicines for the prophylaxis and treatment of osteoporosis. Ir Med J 2008; 101(2): 38-41.
25. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296(24): 2947-2953.
26. Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 2006; 355(17): 1834-1836.
27. Therapeutic Goods Administration. Proton pump inhibitors and possible fracture risk. Australian Adverse Drug Reactions Bulletin 2009; 28(1): 3.
28. de Vries F, Cooper AL, Cockle SM, van Staa TP, Cooper C. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int 2009; 20(12): 1989-1998.
29. Targownik L, Lix L, Leung S, Leslie W. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010; 138: 896-904.
30. Fossmark R, Johnsen G, Johanessen E, Waldum HL. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther 2005; 21(2): 149-154.
31. Horwood J. Clostridium difficile and PPIs. Lancet Infect Diseas 2006; 6(11): 691.
32. Geevasinga N, Kairaitis L, Rangan GK, Coleman PL. Acute interstitial nephritis secondary to esomeprazole. Med J Aust 2005; 182(5): 235-236.
33. Roughead EE, Ramsay EN, Pratt NL, Ryan P, Gilbert AL. Proton-pump inhibitors and the risk of antibiotic use and hospitalisation for pneumonia. Med J Aust 2009; 190(3): 114-116.
34. Talley NJ. Risks of proton-pump inhibitors: what every doctor should know. Med J Aust 2009; 190(3): 109-110.
35. Bajaj JS, Zadvornova Y, Heuman DM, et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol 2009; 104(5): 1130-1134.
36. Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC. Protonpump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 2004; 180(8): 387-391.
37. Sharma P, Morales TG, Bhattacharyya A, Garewal HS, Sampliner RE. Squamous islands in Barrett's esophagus: what lies underneath? Am J Gastroenterol 1998; 93(3): 332-335.
38. Chang JT, Katzka DA. Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma. Arch Intern Med 2004; 164(14): 1482-1488.
39. Shaheen NJ, Richter JE. Barrett's oesophagus. Lancet 2009; 373(9666): 850-861.
40. Nobata K, Asanoi H. Proton pump inhibitor-responsive chronic cough without acid reflux: a case report. J Med Case Reports 2007; 1: 69.
41. Gatta L, Vaira D, Sorrenti G, Zucchini S, Sama C, Vakil N. Metaanalysis: the efficacy of proton pump inhibitors for laryngeal symptoms attributed to gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2007; 25(4): 385-92.
42. Bolton P, Mira M, Kennedy P, Lahra MM. The quality of communication between hospitals and general practitioners: an assessment. J Qual Clin Pract 1998; 18(4): 241-247.
43. Kyle GJ, Nissen LM, Tett SE. The Australian rise of esomeprazole-was expenditure on samples a contributor? Pharmacoepidemiol Drug Saf 2008; 18(1): 62-68.
44. Dhippayom T, Walker R. Impact of the reclassification of omeprazole on the prescribing and sales of ulcer healing drugs. Pharm World Sci 2006; 28(4): 194-198.